Overview

AOD-9604 5 mg is a synthetic hexadecapeptide derived from the C-terminus of human growth hormone (hGH), supplied by
Peptide Tech at ≥ 99% purity (HPLC/MS verified) for in-vitro, cellular, and biochemical research use only (RUO). In controlled lab models, AOD-9604 is used to interrogate lipid-metabolism pathways, β-adrenergic–linked signaling, and peptide stability for analytical method development.

Specifications

CAS Number	221231-10-3
Chemical Name	AOD-9604 (hGH C-terminal analog)
PubChem CID	CID 71300630
Molecular Formula	C₇₈H₁₂₃N₂₃O₂₃S₂
Molecular Weight	≈ 1,815.1 g/mol
Sequence	Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (disulfide Cys₇↔Cys₁₄)
Physical Appearance	White to off-white lyophilized powder
Container	3 mL glass vial (5 mg net content)
Purity	≥ 99% (verified by HPLC & MS; third-party tested)
Solubility	Soluble in sterile water or compatible aqueous buffer; gently swirl to dissolve; 0.22 µm filter-sterilize if required

Molecular Structure

Why Peptide Tech

Same-Day Shipping
GMP-Aligned Lyophilized Peptides
USA Made
24/7 Support
Price Match Guarantee
Batch Tracking with QR Code Verification
3rd-Party USA Lab Testing — purity, quantity, endotoxin
Cold-Chain Shipping — Always (no paid upgrade)
Worldwide Shipping
All Major Payments Accepted
Text & Email Order Updates
2-Day FedEx/UPS Shipping Standard
Cheapest Overnight Rates
Largest Variety of Peptides & Bioregulators

Storage & Handling

Lyophilized (unopened): Store at ≤ −20 °C, protected from light and moisture. For long-term archival, ≤ −80 °C is recommended.
After reconstitution: Aliquot immediately to avoid repeated freeze–thaw; store at ≤ −80 °C (≤ −20 °C acceptable for short-term studies).
General notes: Allow the vial to reach room temperature before opening to minimize condensation. Use sterile technique and compatible buffers; avoid strong acids/bases.
Research Use Only (RUO): Not for human or veterinary use, ingestion, diagnostic, or therapeutic applications.

Potential Applications in Research

Strictly in-vitro, cellular, or biochemical contexts — no clinical or human-use claims.

Adipocyte lipolysis/lipogenesis models: Quantify glycerol/FFA release and lipogenic markers in vitro or ex vivo.
Endocrinology, 2001.
β-Adrenergic pathway interrogation: Explore β₃-AR–related mechanisms in rodent and cell systems.
Endocrinology, 2001.
Hepatocyte/adipocyte enzyme studies: Evaluate effects on lipogenic enzymes (e.g., ACC) and metabolic readouts.
Biochem Mol Biol Int, 1993.
Comparative peptide pharmacology: Contrast AOD-9604 with related hGH fragments in dose/response and stability workflows.
Am J Physiol Endocrinol Metab, 2000.
Pathway-level context (review): Situate findings within broader anti-obesity targets for hypothesis generation.
Clin Pharmacol Ther, 2010.

Citations (PubMed)

Heffernan, M. A., et al. “The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and β₃-AR knock-out mice.” Endocrinology 142(12), 2001, 5182–5189.
PubMed
Heffernan, M. A., Jiang, W. J., Thorburn, A. W., Ng, F. M. “Effects of oral administration of a synthetic fragment of human growth hormone on lipid metabolism.” Am J Physiol Endocrinol Metab 279(3), 2000, E501–E507.
PubMed
Wu, Z., Ng, F. M. “Antilipogenic action of synthetic C-terminal sequence 177–191 of human growth hormone.” Biochem Mol Biol Int 30(1), 1993, 187–196.
PubMed
Valentino, M. A., Lin, J., Waldman, S. A. “Central and peripheral molecular targets for anti-obesity pharmacotherapy.” Clin Pharmacol Ther 87(6), 2010, 652–662.
PubMed

Compliance & RUO Disclaimer

For laboratory research use only (RUO). Not a drug, food, or cosmetic. Not for human or veterinary use. Purchase and use are limited to qualified personnel operating under institutional laboratory guidelines.